The U.S. FDA approved the first of its kind targeted RNA-based therapy Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) caused from hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA approved treatment in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. Read more here.
Recent Posts
- Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
- Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
- The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS
- Top Challenges Faced by Emergency Medicine Residents and How to Overcome Them
- Dry January: Exploring the Health Benefits of Reducing Alcohol Intake